GNI Group Ltd.
Stock Price Chart
2026/08/18 UpdatedPrice Trend
2026/08/18 UpdatedPrice & Trading Details
2026/08/18 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/02/12 | ¥224.64 | ¥-74.44 | -133.1% |
| 2025/11/13 | ¥10.82 | ¥8.54 | -21.1% |
| 2025/08/14 | ¥-109.70 | ¥-7.62 | +93.1% |
| 2025/05/15 | ¥27.86 | ¥-10.57 | -137.9% |
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥12,690M | ¥17,419M | ¥26,011M | ¥23,612M |
| Gross Profit | ¥11,090M | ¥14,745M | ¥22,431M | ¥18,037M |
| Operating Income | ¥1,625M | ¥1,378M | ¥13,109M | ¥1,402M |
| Pretax Income | ¥1,755M | ¥1,638M | ¥13,863M | ¥2,119M |
| Net Income | ¥1,066M | ¥389M | ¥8,094M | ¥1,098M |
| EPS | ¥22.08 | ¥8.11 | ¥165.56 | ¥21.15 |
| Operating Margin | 12.80% | 7.91% | 50.40% | 5.94% |
| Balance Sheet | ||||
| Total Assets | ¥30,296M | ¥33,907M | ¥64,269M | ¥71,943M |
| Total Equity | ¥18,860M | ¥20,970M | ¥33,794M | ¥36,446M |
| Total Liabilities | ¥11,436M | ¥12,937M | ¥30,475M | ¥35,497M |
| Cash | ¥14,352M | ¥11,049M | ¥21,633M | ¥10,115M |
| Interest-bearing Debt | ¥1,126M | ¥537M | ¥3,699M | ¥7,206M |
| Equity Ratio | 62.25% | 61.84% | 52.58% | 50.66% |
| D/E Ratio | 0.06 | 0.03 | 0.11 | 0.20 |
| Cash Flow | ||||
| Operating CF | ¥552M | ¥393M | ¥6,549M | -¥3,164M |
| Investing CF | -¥261M | -¥4,116M | -¥6,843M | -¥10,361M |
| Financing CF | ¥2,853M | -¥646M | ¥10,687M | ¥694M |
| Free CF | -¥142M | -¥1,547M | ¥4,473M | -¥4,701M |
| Efficiency | ||||
| ROE | 5.65% | 1.85% | 23.95% | 3.01% |
| ROA | 3.52% | 1.15% | 12.59% | 1.53% |
Latest IR Information
-
[Company Name] Toward a Second Founding: Group-wide Synergy (Itchiness) | Global BioPharma
A material outlining a growth strategy through group-wide integration and partnerships. Focus on business expansion via M&A and collaborations and the restructuring of mid- to long-term strategy. Specific monetary figures are not disclosed, so qualitative explanations are primary.
Read more -
Notice on the Completion of Acquisition of All Shares of Ayumi Pharmaceutical Holdings Co., Ltd. (Full Subsidiary) and Full Payment for New Shares Issued through Third-Party Allotment (In-Kind Contribution)
Completed acquisition to become a wholly owned subsidiary and issuance of new shares through a third-party allotment. Payment date is July 1, 2026; issued shares: 9,974,291; issue price: 2,684 JPY per share; funds raised: approximately 26.771 billion JPY. Invested entities:...
Read more -
【G.N.Airloop】June 2026 Financial Results | Details of Fundraising and Financial Covenants
G.N.Airloop signed a loan agreement for fund-raising on June 26, 2026, with financial covenants set to maintain capital and achieve profitability from the fiscal year ending December 2026 onward. The funds raised amount to 20,000 million yen, with collateral provided...
Read more -
[GN All-loop Group] Payment Date for New Share Issue Confirmed | July 2026
GN All-loop Group has confirmed the payment date for the new share issuance via third-party allotment scheduled for July 1, 2026, and plans to issue approximately 9,974,291 shares. This represents an important capital policy measure for fund raising.
Read more -
Gyre Therapeutics Submit Form S-3 Registration Statement｜June 2026
Gyre Therapeutics has submitted a Form S-3 registration statement to the U.S. Securities and Exchange Commission to facilitate the sale of shares associated with the full acquisition of Cullgen. Currently, our holdings of Gyre shares are approximately 70%, and there...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥4,400
Rating Score: 1.00 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
